Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Ha Il Kim"

Article category

Keywords

Publication year

"Ha Il Kim"

Original Articles

Hepatic neoplasm

Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
Clin Mol Hepatol 2023;29(4):1013-1028.
Published online July 5, 2023
DOI: https://doi.org/10.3350/cmh.2023.0131
Background/Aims
There is no clear consensus on the relative ranking of interventional and radiation techniques with indications similar to those of radiofrequency ablation (RFA) for the treatment of early hepatocellular carcinoma (HCC). We used a network meta-analysis to compare the efficacy of non-surgical treatments for early HCC.
Methods
We searched databases for randomized trials assessing the efficacy of loco-regional treatments for HCCs ≤5 cm with no extrahepatic spread or portal invasion. The primary outcome was the pooled hazard ratio (HR) for overall survival (OS), and secondary outcomes included overall and local progression-free survival (PFS). A frequentist network meta-analysis was performed, and the relative ranking of therapies was assessed with P-scores.
Results
Nineteen studies comparing 11 different strategies in 2,793 patients were included. Chemoembolization plus RFA improved OS better than RFA alone (HR 0.52, 95% confidence interval [CI] 0.33–0.82; P-score=0.951). Cryoablation, microwave ablation, laser ablation, and proton beam therapy had similar effects on OS compared with RFA. For overall PFS, but not local PFS, only chemoembolization plus RFA performed significantly better than RFA (HR 0.61, 95% CI 0.42–0.88; P-score=0.964). Injection of percutaneous ethanol or acetic acid was significantly less effective than RFA for all measured outcomes, while no differences in progression outcomes were identified for other therapies included in the network.
Conclusions
Our results suggest that chemoembolization combined with RFA is the best option for local treatment of early HCC. Cases with potential contraindications for RFA may benefit from a tailored approach using thermal or radiation modalities.

Citations

Citations to this article as recorded by  Crossref logo
  • A network meta-analysis of different interventional treatment strategies for unresectable hepatocellular carcinoma
    Xing-Yan Le, Jun-Bang Feng, Xiao-Li Yu, Sui-Li Li, Xiaocai Zhang, Jiaqing Li, Chuan-Ming Li
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Association between early job loss and prognosis among hepatocellular carcinoma survivors
    B Yun, J Oh, S H Ahn, B K Kim, J-H Yoon
    Occupational Medicine.2025; 75(2): 113.     CrossRef
  • The Emerging Landscape for Combating Resistance Associated with Energy‐Based Therapies via Nanomedicine
    Qitao Hu, Huali Zuo, Jessica C. Hsu, Cheng Zeng, Zhou Tian, Zhouyi Sun, Weibo Cai, Zhe Tang, Weiyu Chen
    Advanced Materials.2024;[Epub]     CrossRef
  • Efficacy and Safety of CT-guided Percutaneous Cryoablation for Hepatocellular Carcinoma at High-risk Sites
    Weihao Zhang, Yan Wang, Xiaohui Zhao, Wei Gao, Changfu Liu, Tongguo Si, Xueling Yang, Wenge Xing, Haipeng Yu
    Academic Radiology.2024; 31(11): 4434.     CrossRef
  • Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
    Hyo-Cheol Kim
    Clinical and Molecular Hepatology.2023; 29(4): 984.     CrossRef
  • 8,108 View
  • 180 Download
  • 5 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
Jihyun An, Hyung-Don Kim, Seon-Ok Kim, Ha Il Kim, Gi-Won Song, Han Chu Lee, Ju Hyun Shim
Clin Mol Hepatol 2022;28(1):67-76.
Published online October 12, 2021
DOI: https://doi.org/10.3350/cmh.2021.0202
Background/Aims
We aimed to investigate the silent atherosclerotic burden of cervicocephalic vessels in cirrhotic patients compared with the general population, as well as the relevant risk factors including coronary parameters.
Methods
This study included 993 stroke-free patients with liver cirrhosis (LC) who underwent magnetic resonance angiography (MRA) of the head and neck as a pre-liver transplant assessment and 6,099 health checkup participants who underwent MRA examination. The two cohorts were matched for cerebrovascular risk factors, and the prevalence of atherosclerosis in major intracranial and extracranial arteries was compared in 755 matched pairs. Moreover, traditional, hepatic, and coronary variables related to cerebral atherosclerosis were assessed in cirrhotic patients.
Results
Overall, intracranial atherosclerosis was significantly less prevalent in the LC group than in the matched control group (2.3% vs. 5.4%, P=0.002), whereas the prevalence of extracranial atherosclerosis was similar (4.4% vs. 5.8%, P=0.242). These results were maintained in multivariate analyses of the pooled samples, with corresponding adjusted odds ratios [ORs] of LC of 0.56 and 0.77 (95% confidence intervals [CIs], 0.36–0.88 and 0.55–1.09). In the LC group, lower platelet count was inversely correlated with intracranial atherosclerosis (adjusted OR, 0.31; 95% CI, 0.13–0.76). Coronary artery calcium (CAC) score ≥100 was the only predictive factor for both intracranial and extracranial atherosclerosis (adjusted ORs, 4.06 and 5.43, respectively).
Conclusions
LC confers protection against intracranial atherosclerosis, and thrombocytopenia may be involved in this protective effect. High CAC score could serve as a potential surrogate for cervicocerebral vascular screening in asymptomatic cirrhotic patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
    Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei
    Clinical and Molecular Hepatology.2022; 28(2): 265.     CrossRef
  • Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis
    Jihyun An, Ju Hyun Shim
    Clinical and Molecular Hepatology.2022; 28(2): 267.     CrossRef
  • 8,020 View
  • 186 Download
  • 2 Web of Science
  • Crossref